EMA proposes 10 recommendations to unlock potential of big d...

European regulators have proposed ten recommendations that aim to unlock the potential of big data for public health in the EU.

EMA counts the cost of Brexit in lost staff and narrower wor...

Merck’s last-resort antibiotic Recarbrio nears EU approval

EMA resolves dispute over pricey Canary Wharf tenancy

Alexion’s Soliris follow-up Ultomiris snares EU approval

Mitsubishi Tanabe pulls ALS drug from EMA assessment

Mitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements from the EMA.